

CUMULATIVE INDEX 1996

Volume 17

March	THE LUNG IN LIVER DISEASE, pages 1-173
June	THE SEPSIS SYNDROME, pages 175-353
September	RECENT ADVANCES IN MECHANICAL VENTILATION, pages 355-619
December	PULMONARY COMPLICATIONS OF HIV INFECTION, pages 621-822

Note: Page numbers of article titles are in **boldface** type.

ABGs. See *Arterial blood gas(es)*.

Abscess(es), lung, in illicit drug users, 801

N-Acetylcysteine, for ARDS, 227
for sepsis, 297-299

Acquired immunodeficiency syndrome (AIDS). See also *Human immunodeficiency virus (HIV) infection*.

acute respiratory failure in, noninvasive ventilation for, 530-531

defined, 621

interstitial lung disease and, 634

macrophage alveolitis and, mechanisms in, 638

Pneumocystis carinii pneumonia and, 621

prevalence, 621

pulmonary complications, demographic factors in, 624-625

ACTG 116B/117, for HIV infection, 651-652

ACTG 155, for HIV infection, 652-653

ACTG 175, for HIV infection, 650-652, 653

ACTG 229, for HIV infection, 653

Acute lung injury, current concepts of, 213-235

ventilatory management of, pressure-targeted approach to, 571-572

Acute respiratory distress, mechanical ventilation and, 441-442

Acute respiratory distress syndrome (ARDS),

barotrauma versus volutrauma in, 560

mechanical ventilation in, modes of, 570-571

noninvasive ventilation for, 528-529

PEEP in, 560-563

permissive hypercapnia in, 565

tidal compliance in, 563

tidal recruitment in, 563

ventilator-induced, 556-560

ventilatory management of, 555-575

adjuncts to, 565-570

extrapulmonary gas exchange, 566

high-frequency ventilation in, 563-566

nitric oxide, 568-570

partial liquid ventilation, 567-568

pressure-targeted approach to, 571-572

prone positioning, 566-567

prostacyclin, 568-570

surfactant administration, 566

tracheal gas insufflation, 568

Acute respiratory failure (ARF), described, 513

hypoxemic, pediatric, noninvasive ventilation for, 532-533

in asthmatics, noninvasive ventilation for, 522-524

in *Pneumocystis carinii* pneumonia, prognostic markers of, 676-678

noninvasive ventilation for, 513-553. See also *Noninvasive ventilation*.

postextubation, and difficult weaning, 533-535

Adenovirus infection, of lung, in HIV infection, 750

Adhesion molecules, in lipopolysaccharide-induced sepsis syndrome, 190-191

Adenoviral infections, following liver transplantation, 108

Adrenergic drugs, gas exchange effects on, 60

Adult respiratory distress syndrome (ARDS), N-acetylcysteine for, 227

anti-cytokines for, 226-227

anti-endotoxins for, 226-227

as component of multiple-organ dysfunction syndrome, 216

causes, 215

clinical evaluation, 216

corticosteroids for, 226

CT in, 216-217

defined, 213

described, 128

epidemiology, 214-216

fiberoptic bronchoscopy in, 217

following liver transplantation, 104-105

in acute lung injury, 128

in liver cirrhosis, 147-148

in sepsis, 213-235

frequency of, 215-216

ketoconazole for, 227

mechanical ventilation in, 229

nitric oxide for, 228

outcome from, 230

perflubron for, 227-228

permissive hypercapnia in, 229

prevalence, 214-216

prone position ventilation in, 229-230

- Adult respiratory distress syndrome (ARDS) (*Continued*)
 pulmonary edema in, treatment, 229
 pulmonary intravascular phagocytosis and, 148-149
 sepsis in, treatment, 228
 surfactant replacement for, 227
 treatment, 226-228
 vasodilators for, 227
 Afterload, defined, 238
 AIDS. See *Acquired immunodeficiency syndrome*.
 Airway(s), difficult, tube placement into, 355
 Airway disease, upper, in HIV-infected children, 792
 Airway management, in critically ill patients, algorithm for, 358
 prolonged, intubation for, 370-371
 tracheotomy for, 371-372
 Airway occlusion pressure, during mechanical ventilation, 460
 Airway pressure(s), in respiration, 577-579
 Airway pressure profile, during mechanical ventilation, measurement of, 465
 Airway resistance, in COPD, 579-580
 Almitrine bismesylate, gas exchange effects on, 59-60
 Alveolar macrophages, in lungs of HIV-infected patients, 638-640
 cytokine release, 639-640
 phenotypic features, 638-639
 Alveolitis, lymphocytic, HIV-related, pathogenesis, 635-636
 in HIV infection, 765-766
 macrophage, AIDS-related, mechanism in, 638
 neutrophilic, in HIV-infected patients, 640
 Aminoglycoside(s), for sepsis, 179
 Amphotericin B, for cryptococcosis, 728-729
 Anastomosis(es), portal vein-to-pulmonary vein, in chronic liver disease, 3-6
 pulmonary artery-to-pulmonary vein, through pleural channels, in chronic liver disease, 2-3
 Anergy testing, in HIV-infected patients, 699
 Angiography, pulmonary, in hepatopulmonary syndrome, 42-44
 Anti-cytokine(s), for ARDS, 226-227
 for sepsis, 310-313
 Anti-endotoxin(s), for ARDS, 226-227
 for sepsis, 309-310
 Antioxidant(s), as inflammatory mediator in sepsis, 205
 for sepsis, 295-297
 Antiretroviral therapy, for HIV infection, 647-662. See also specific drugs and *Human immunodeficiency virus (HIV) infection, antiretroviral therapy for*.
 α_1 -Antitrypsin deficiency, 67-74
 described, 67-70, 151-152
 features, 152
 medical therapy for, 71-72
 National Institutes of Health Registry for, 73-74
 natural history, 70-71
 organ transplantation for, expectations from, 72-73
 treatment, 152
 Arachidonic acid metabolites, in hepatopulmonary syndrome, 154
 in lipopolysaccharide-induced sepsis syndrome, 190
 ARDS. See *Acute respiratory distress syndrome*; *Adult respiratory distress syndrome*.
 L-Arginine-nitrous oxide pathways, biochemical aspects of, 334
 Arterial blood gas(es) (ABGs), measurement of, 453-454
 timing of sampling, 453-454
 Arterial blood gas (ABG) analysis, in pulmonary disease evaluation in HIV-infected patients, 771-772
 Arteriovenous shunting, in liver cirrhosis, 50-51
 Aspergillosis, 739-741
 clinical features, 739-740
 diagnosis, 740
 epidemiology, 739
 microbiology of, 739
 prevention, 741
 treatment, 740-741
 Aspiration, interbronchial, 597
 Aspirin, for sepsis, 290-291
 Asthma, acute respiratory failure in, noninvasive ventilation for, 522-524
 HIV infection in illicit drug users and, 804
 Atelectasis, acute respiratory failure in, noninvasive ventilation for, 532
 following liver transplantation, 104
 HIV infection in illicit drug users and, 804
 Atrial natriuretic factor (ANF), in hepatopulmonary syndrome, 153-154
 Augustine Guide, for orotracheal intubation, 362, 363
 Auto-PEEP. See *Auto-positive end-expiratory pressure (PEEP)*.
 Auto-positive end-expiratory pressure (PEEP), and dynamic hyperinflation, 379-394
 with flow limitation, 380-383
 without flow limitation, 383-385
 described, 379
 during mechanical ventilation, measurement of, 464-465
 in clinical management, 388-391
 in COPD, 379-394
 in pressure-controlled ventilation, 401, 403
 in respiration, 577-579
 in volume-cycled ventilation, 396-398
 measurement of, 388-391
 physiologic mechanisms of, 380-388
 rationale for, 380-388
 without dynamic hyperinflation, 385-388
 AZT. See *Zidovudine*.
 Bacteremia, defined, 175
 Bacteria, gram-negative, sepsis syndrome due to, 183-184
 Bacterial infections, in HIV-infected children, 791
 in HIV-infected patients, fiberoptic bronchoscopy for, 776-777
 Barbiturate(s), for translaryngeal intubation, 366
 Barotrauma, during mechanical ventilation, 445
 versus volutrauma, in ARDS, 560
 Baseline pressure, minimization of, 412
 Benzodiazepine(s), for translaryngeal intubation, 366
 Bile duct ligation model, in experimental liver disease, 141-143
 Biliary cirrhosis, rats with, hemodynamic studies, 137-138
 Blastomycosis, 736-737
 clinical features, 737
 diagnosis, 737
 epidemiology, 736-737
 microbiology of, 736
 prevention, 737
 treatment, 737
 Blood cultures, in sepsis, 177-178
 Blood gas(es), arterial, in hepatopulmonary syndrome, 40-41
 Blood tests, in pulmonary disease evaluation in HIV-infected patients, 772-773
 BMS 019, for HIV infection, 652
Bordetella sp., infections due to, in HIV-infection, 751
 Bougie, gum elastic, 359, 360

- Bradykinin antagonists, for sepsis, 200
 Breath(s), pressure-limited, enhancements in, 415-416
 Breathing, work of, during mechanical ventilation, measurement of, 467
 Breathing pattern, measurement of, during mechanical ventilation, 460-462
 Bristol-Myers Squibb 010, for HIV infection, 652
 Bronchiectasis, in illicit drug users, 801
 Bronchitis, in illicit drug users, 801
 Bronchoalveolar lavage (BAL), in pulmonary complications of HIV infection, 632
 Bronchodilator(s), in respiration, 586-588
 Bronchogenic carcinoma, HIV infection in illicit drug users and, 804
 Bronchopleural fistula, lung separation due to, 598-599
 Bronchopulmonary dysplasia (BPD), 603
 Bronchoscope(s), flexible fiberoptic, translaryngeal intubation with, 358
 Bronchoscopy, fiberoptic, in ARDS evaluation, 217
 in pulmonary disease evaluation in HIV-infected patients, 775-778
 Bullous disease, HIV infection in illicit drug users and, 801-802
- Calcification, pulmonary, following liver transplantation, 105-106
 Calcitonin gene-related peptide (CGRP), in hepatopulmonary syndrome, 153
 Calcium homeostasis, alterations in, in sepsis-induced metabolic alterations, 255-257
 Cancer, lung, in HIV-infected patients, 759-760
Candida species, hepatic cytokine production in, 89-90
 Candidiasis, 741-743
 clinical features, 741-742
 diagnosis, 742
 epidemiology, 741
 in HIV infection, 726
 prevalence, trends in, 623
 prevention, 742-743
 treatment, 742
 Capillary(ies), alveolar, dilated, in chronic liver disease, 6-8
 Capnography, 457-460
 Carbon dioxide removal, during high-frequency ventilation in newborns, 611
 extracorporeal, in mechanical ventilation, 492-493
 in mechanical ventilation, adjuncts to, 492-498
 in neonatal mechanical ventilation, 608-609
 Carbontetrachloride model, in experimental liver disease, 143-144
 Cardiac dysfunction, during septic shock, 237-248. See also *Septic shock, cardiac dysfunction during*.
 Cardiogenic pulmonary edema, acute respiratory distress in, noninvasive ventilation for, 526-528
 Catheter(s), endotracheal tube exchange over, 359, 361
 gum elastic bougie, 359, 360
 CD4+ cells, in lungs of HIV-infected patients, 634-635
 CD8 cells, in lungs of HIV-infected patients, 635
 Cefuroxime, for sepsis, 179
 Chest radiography, in pulmonary disease evaluation in HIV-infected patients, 768-769
 Children, HIV infection in, 787-796. See also *Human immunodeficiency virus (HIV) infection, in children*.
 hypoxemic acute respiratory failure in, noninvasive ventilation for, 532-533
 Chronic obstructive pulmonary disease (COPD), airway resistance in, 579-580
 auto-PEEP in, 379-394, 577-579
 bronchodilators in, 586-588
 controlled hypoventilation with permissive hypercapnia, 585-586
 corticosteroids in, 586-588
 expiratory flow limitation in, 580-581
 mechanical ventilation in, 577-590
 pulmonary hyperinflation, 581-585
 respiratory mechanics, 577-581
 noninvasive ventilation for, 516-522
 outcome following, 588
 PEEP in, 580-581
 Cidofovir, for CMV, 659
 Circuit resistance, in mechanical ventilation, 432
 Cirrhosis, biliary, rats with, hemodynamic studies, 137-138
 hypoxic pulmonary vasoconstriction in, 138-140
 liver, 49-66
 ARDS in, 147-148
 chronic, pulmonary intravascular macrophages in, 132-133
 gas exchange impairment in, at rest, 50-55
 mechanisms of, 49-66
 pathogenesis, 58-59
 pulmonary intravascular macrophages in, induction of, mechanisms for, 145-146
 vascular permeability changes in, 140-141
 primary biliary, 74-75
 Clindamycin-primaquine, for *Pneumocystis carinii* pneumonia, 682-683
 Coaxial techniques, in lung separation, 592
 Coccidioidomycosis, 733-736
 clinical features, 734
 diagnosis, 734-735
 epidemiology, 734
 microbiology of, 733-734
 prevention, 735-736
 treatment, 735
 Colony-stimulating factors, in sepsis, 320
 Complement, as inflammatory mediator in sepsis, 203
 in lipopolysaccharide-induced sepsis syndrome, 190
 Compliance, effective dynamic, during mechanical ventilation, measurement of, 463
 static, during mechanical ventilation, measurement of, 462-463
 Computed tomography (CT), in ARDS evaluation, 216-217
 in pulmonary disease evaluation in HIV-infected patients, 768-769
 Computer(s), in weaning from mechanical ventilation, 486
 Continuous positive airway pressure (CPAP), for COPD patients with acute respiratory failure, 516
 mask, clinical application of, 518-520
 COPD. See *Chronic obstructive pulmonary disease*.
 Corticosteroid(s), for ARDS, 226
 for *Pneumocystis carinii* pneumonia, 683-684
 gas exchange effects on, 60
 in respiration, 586-588
 Cricothyroidectomy, 360
 Cryptococcosis, 727-730
 clinical features, 728
 diagnosis, 728
 epidemiology, 727-728
 in HIV-infection, 726
 microbiology of, 727
 prevalence, trends in, 623
 prevention, 730
 treatment, 728-730
 Cryptosporidiosis, bronchopulmonary, in HIV infection, 750-751

- Cryptosporidiosis (*Continued*)
 prevalence, trends in, 623
 CT. See *Computed tomography*.
 Cyclooxygenase inhibitors, for sepsis, 289-292
 Cyclophosphamide, gas exchange effects on, 60
 Cystic fibrosis, and lung transplantation, acute
 respiratory failure associated with, noninvasive
 ventilation for, 525
 Cytokine(s), as inflammatory mediator in sepsis,
 203-204
 biology, in liver disease, 89
 induction of, in lipopolysaccharide-induced sepsis
 syndrome, 185-190
 kinetics, during nonbacteremic versus bacteremic he-
 patic oxidative stress, 90
 macrophage-derived, lung damage due to, 640
 release of, by alveolar macrophages in HIV-infected
 patients, 639-640
 transcription and secretion of, in sepsis-induced lung
 injury, 218-219
 Cytomegalovirus (CMV) infection, following liver
 transplantation, 107-108
 in HIV-infected children, 790
 in HIV-infected patients, blood tests for, 773
 new developments in, 658-660
 prevalence, trends in, 623
 Cytomegalovirus (CMV) pneumonitis, in HIV infection,
 746-748
- ddC, for HIV infection, 650
 ddI, for HIV infection, 650-651
 Dobutamine, for sepsis, 282-283
 Dopamine, for sepsis, 282
 Drug users, illicit, HIV infection in, 797-807. See also
 Human immunodeficiency virus (HIV) infection, in
 illicit drug users.
 Dynamic hyperinflation, in mechanical ventilation,
 429-430
 ventilatory determinants of, 582-583
- Echocardiography, contrast-enhanced, in
 hepatopulmonary syndrome, 41-42
 Edema, pulmonary, cardiogenic, acute respiratory
 distress in, noninvasive ventilation for, 526-528
 in liver transplant recipients, 100-101
 Education, for noninvasive ventilation, 545
 Effusion(s), pleural, 76-77
 following liver transplantation, 104
 in liver transplant recipients, 101-102
 Emphysema, HIV infection in illicit drug users and,
 801-802
 End-expiratory lung volume, importance of, in ARDS,
 560-563
 Endobronchial blockers, in lung separation, 591
 Endocarditis, in illicit drug users, 800-801
 Endothelial activation, nitric oxide and, 341
 Endothelial cells, as inflammatory mediator in sepsis,
 207-209
 Endothelium, described, 21
 Endothelium-derived relaxing factor, 154-155
 Endotoxemia, pulmonary intravascular macrophages in,
 132-133
 Endotoxin, as inflammatory mediator in sepsis, 201-203
 Endotracheal intubation, equipment for, 362-366
 Endotracheal tube(s), blood from, during mechanical
 ventilation, 446-447
 double-lumen, for endotracheal intubation, 362, 363
 in lung separation, 592-596
 in lung separation, 591-592
 malposition of, complications due to, 369
 Endotracheal tube exchange over a catheter, 359, 361
 Epinephrine, for sepsis, 282
 Epithelial cells, in inflammatory cell activation in sepsis,
 208-209
 Epstein-Barr virus (EBV), following liver
 transplantation, 108
 of lung, in HIV infection, 749
 Erythromycin, for sepsis, 179
 E-selectin, in sepsis-induced lung injury, 220
 Esophageal tubes, placement of, detection of, 365-366
 Esophageal-tracheal Combitube (ETC), for endotracheal
 intubation, 364-365
 Estrogen, and induction of pulmonary intravascular
 macrophages in liver cirrhosis, 145-146
 Ethical issues, in intubation, 372-373
 Etomidate, for translaryngeal intubation, 366
 Exercise, gas exchange during, 55-58
 Expiratory flow limitation, assessment, 391
 in COPD, 580-581
 Extrapulmonary gas exchange, in ARDS, 566
 Extrapulmonary infection, *Pneumocystis carinii*
 pneumonia and, 678-679
 Extubation, criteria for, in weaning from mechanical
 ventilation, 478
 tracheal, 369-370
- Facial skin necrosis, noninvasive ventilation and, 545
 Fcγ receptors, in lipopolysaccharide-induced sepsis
 syndrome, 191
 Fentanyl, for translaryngeal intubation, 367
 Fiberoptic bronchoscopy, in ARDS evaluation, 217
 in pulmonary disease evaluation in HIV-infected pa-
 tients, 775-778
 Fighting the ventilator, mechanical ventilation and,
 441-442
 Fistula(s), bronchopleural, lung separation due to,
 598-599
 Flow delivery, in mechanical ventilation, 431-432
 Flow limitation, auto-PEEP and dynamic hyperinflation
 with, 380-383
 auto-PEEP and dynamic hyperinflation without, 383-
 385
 Flow profile, in volume-cycled ventilation, 399-400
 Flow rate, in volume-cycled ventilation, 398-399
 Flow-volume curves, during mechanical ventilation,
 measurement of, 465-466
 Fluconazole, for cryptococcosis, 728-730
 Flucytosine, for cryptococcosis, 728-730
 Fluid(s), in sepsis, 279-281
 Flumazenil, for translaryngeal intubation, 366
 Fosarnet, for CMV, 659
 Fungal infections, in HIV-infected children, 791
 in HIV-infected patients, 725-744
 blood tests for, 772-773
 overlap disease, 741-743
 phagocyte opportunists in, 739-741
 T-cell opportunists in, 727-739
 new developments in, 657
 Fungal pneumonia, following liver transplantation, 109
 in illicit drug users, 801
 Fungal sepsis, hepatic cytokine production in, 89-90
- Gallium (Ga-67) scanning, in pulmonary disease
 evaluation in HIV-infected patients, 769-771

- Ganciclovir, for CMV, 659, 660
- Gas exchange, at rest, 50-55
 historical background, 50-51
 MIGET, 51-55
 during exercise, 55-58
 during mechanical ventilation, 453-460
 external intervention effects on, 59-62
 extrapulmonary, in ARDS, 566
 impairment in, in liver cirrhosis, mechanisms of, 49-66. See also under *Cirrhosis, liver, gas exchange impairment in*.
 perfluorocarbon-associated, for improving oxygenation, in mechanical ventilation, 502-504
- Gastric distention, noninvasive ventilation and, 544
- Gastrointestinal tract, nitric oxide and, 342
- Glucagon, in hepatopulmonary syndrome, 152-153
- Glucose, metabolism of, in sepsis, 251-253
- Granulocyte colony-stimulating factor, and neutrophil function, 322-323
 in infected hosts, 323-327
 in sepsis, 320-322
- Gum elastic bougie, 359, 360
- Haemophilus influenzae*, in HIV-type 1 infection, 713, 714-715
- Heart, physiology of, 237-238
- Hemoptysis, massive, 596
- Hepatic cytokine secretory capacity, 88-89
- Hepatic hydrothorax, 76-77
- Hepatic oxidative stress, nonbacteremic versus bacteremic, cytokine kinetics during, 90
- Hepatic veno-occlusive disease, 76
- Hepatitis C, chronic, 75-76
- Hepatocyte growth factor/scatter factor, 157-162
 biologic properties, 160-162
 described, 157-158
 genomic structure, 158-159
 protein-structure-function relationships, 159
- Hepatocyte growth factor/scatter factor receptor, 159-160
- Hepatopulmonary syndrome, 1, 35-48, 152-155
 animal models of, 137-141
 clinical manifestations, 39-40
 described, 35
 diagnostic modalities in, 40-44
 hypoxemia in, mechanism of, 36-37
 intrapulmonary vascular dilatations in, mechanism of, 37-38
 liver diseases associated with, 39
 liver transplantation for, 115-123
 early history, 115-116
 future prospects, 121
 recent experience with, 116-118
 remaining uncertainties associated with, 121
 resolution following, 119-121
 pathophysiology, 36
 pulmonary hemodynamics, 38-39
 resolution of, following liver transplantation, 119-121
 reversibility of, predictors of, 118-119
 treatment, 44-46
- Herpes simplex virus (HSV), following liver transplantation, 108
- Herpes simplex virus (HSV) pneumonitis, in HIV infection, 748-749
- Herpesvirus infections, in HIV infection, 746-749
- High-frequency ventilation (HFV), 417-419
 in ARDS, 563-566
- High-pressure alarm, repeated, mechanical ventilation and, 442-445
- Histoplasmosis, 730-733
 clinical features, 731-732
 diagnosis, 732
 epidemiology, 730-731
 in HIV-infected patients, blood tests for, 772-773
 microbiology of, 730
 prevention, 733
 treatment, 733
- HIV infection. See Human immunodeficiency virus (HIV) infection.
- Homeostasis, calcium, alterations in, in sepsis-induced metabolic alterations, 255-257
 normal, 255-257
- HSV. See *Herpes simplex virus*.
- Human immunodeficiency virus (HIV) infection. See also *Acquired immunodeficiency syndrome*.
 ACTG 116B/117 for, 651-652
 ACTG 155 for, 652-653
 ACTG 175 for, 650-652, 653
 ACTG 229 for, 653
 anergy testing in, 699
 antiretroviral therapy for, 647-662
 ACTG 116B/117, 652
 ACTG 155, 653
 ACTG 175, 651, 653
 ACTG 229, 654
 AZT, 647, 649-650
 BMS 019, 653
 Bristol-Myers Squibb 010, 652-653
 ddC, 650
 ddl, 650
 NUCA 3001, 652
 NUCA 3002, 654
 NUCB 3002, 654
 AZT for, 649-655
 BMS 019 for, 652
 Bristol-Myers Squibb 010 for, 652
 clinical manifestations, 647-662
 ACTG 175, 650-652
 CMV and, blood tests for, 773
 ddC for, 650
 ddl for, 650-651
 immune function affected by, 623-624
 in children, 787-796
 bacterial infections, 791
 clinical course of, 788
 CMV infection, 790
 fungal infections, 791
 Kaposi's sarcoma, 792
 maternal-fetal transmission, 787-788
 Mycobacterium avium-intracellulare infection, 790
 noninfectious disorders, 791-792
 opportunistic infections, 788-791
 Pneumocystis carinii pneumonia, 788-789
 tuberculosis, 789-790
 upper airway disease, 792
 viral infections, 790-791
 with respiratory symptoms, 792
 in illicit drug users, 797-807
 noninfectious complications, 801-804
 pathophysiology, 798-799
 pulmonary infections due to, 799-801
 in its second decade, 792
 inhaled, HIV infection in, 804-805
 intensive care of patients with, 627-629
 lymphocytic alveolitis in, 765-766
 lymphocytic interstitial pneumonitis in, 763-766
 malignancies with, Kaposi's sarcoma, 755-758
 lung cancer, 759-760
 non-Hodgkin's lymphoma, 758-759

- Human immunodeficiency virus (HIV) infection (*Continued*)
- pulmonary complications, 755-761
 - mycobacterial complications, 697-711
 - diagnosis, 699-700
 - mycobacterial diseases with, 701
 - new developments in, 655-660
 - nonspecific interstitial pneumonitis in, 764-765
 - NUCA 3001 for, 651
 - NUCA 3002 for, 653
 - NUCB 3002 for, 653
 - of lung T lymphocytes, 641-642
 - of pulmonary macrophages, 641
 - pathogenesis of, 647-649
 - Pneumocystis carinii* pneumonia and, 621. See *Pneumocystis carinii* pneumonia, in HIV-infected patients.
 - pulmonary complications, alveolar macrophages in, 638-640
 - approach to patients with, 767-785
 - arterial blood gas analysis for, 771-772
 - blood tests for, 772-773
 - bronchoalveolar lavage for, 633
 - chest radiography for, 768-769
 - CT for, 768-769
 - fiberoptic bronchoscopy for, 775-776
 - fungal, 725-744. See also *Fungal infections, in HIV-infection.*
 - immunologic-related, 633-645
 - lymphocyte compartmentalization, 634-638
 - overview, 621-631
 - pleural disease, 778-780
 - polymorphonuclear cells, 640-641
 - pulmonary function tests for, 771
 - pulse oximetry for, 772
 - radionuclide scans for, 769-771
 - respiratory symptoms, 625-626
 - sputum examination for, 773-775
 - TCR repertoire in, 636-637
 - thoracoscopy for, 778
 - thoracotomy for, 778
 - trans thoracic needle aspiration for, 778
 - types, 626-627
 - pulmonary defenses and, 633-641
 - pulmonary function in, 626
 - pulmonary immunocompetent cells in, 641-642
 - tuberculin skin testing in, 699
 - tuberculosis and, 697-702. See also *Tuberculosis, in HIV-infected patients.*
 - viral infections in, 745-754. See also *Viral infections, pulmonary, in HIV-infection.*
- Human immunodeficiency virus (HIV) infection study, pulmonary complications, 624
- Human immunodeficiency virus (HIV) infection-type 1, bacterial pneumonia associated with, 713-723
- clinical manifestations, 716
 - diagnosis, 716-718
 - epidemiology, 714-715
 - pathophysiology, 713-714
 - prevention, 720-721
 - treatment, 718-720
- nosocomial pneumonia in, 715-716
- Human immunodeficiency virus (HIV) infection-type 1 RNA quantitation, in clinical practice, 655-656
- Hypercapnia, permissive, controlled hypoventilation with, 585-586
- in ARDS, 229, 565
- Hypercapnic respiratory failure, noninvasive ventilation for, 516
- Hyperinflation, complications of, 583-584
- assessing risk of, 584-585
- dynamic, auto-PEEP and, 379-394
- auto-PEEP without, 385-388
 - in mechanical ventilation, 429-430
 - ventilatory determinants of, 582-583
- pulmonary, in COPD, 581-585
- Hypertension, portal noncirrhotic, 76
- pulmonary. See Pulmonary hypertension.
- Hypotension, mechanical ventilation and, 440-441
- Hypoventilation, controlled, with permissive hypercapnia, 585-586
- in liver cirrhosis, 50
- Hypoxemia, arterial, in liver transplant recipients, 99-100
- mechanical ventilation and, 445-446
 - mechanism of, 36-37
 - transient, noninvasive ventilation and, 544-545
- Hypoxemic respiratory failure, noninvasive ventilation for, 525-526
- Hypoxic pulmonary vasoconstriction (HPV), in cirrhosis, 138-140
- Ibuprofen, for sepsis, 291-292
- Imipenem, for sepsis, 179
- Immune system, HIV infection effects on, 633-645. See also *Human immunodeficiency virus (HIV) infection, pulmonary complications.*
- respiratory tract-related, components of, 633-634
- Immunity, nitric oxide and, 342
- Immunosuppression, advanced, defined, 621
- Immunotherapy, for sepsis, 307-317
- Impedance, components of, 395
- Independent lung ventilation, 591-601
- clinical considerations, 596-599
- Infection(s), defined, 175
- extrapulmonary, *Pneumocystis carinii* pneumonia and, 678-679
 - gram-negative, pathogenesis, 307-309
- Infectious diseases, prevalence, trends in, 623
- Inflammation, in sepsis, mediators and modulators of, 201-205
- Inflammatory cascade, interleukin-1 β 's effects on, in lipopolysaccharide-induced sepsis syndrome, 188
- tumor necrosis factor- α 's effects on, in lipopolysaccharide-induced sepsis syndrome, 186-187
- Inflammatory cell activation, in sepsis, markers of, 205-209
- Inflammatory mediators, in sepsis-induced MOFS, hepatic production and export of, 88-90
- metabolic inactivation of, 90-91
- Inflammatory reaction, nitric oxide during, 336-337
- Inflammatory response, modulation of, hepatic acute-phase protein synthesis in, 91-93
- Influenza, in HIV-infection, 749
- Inotropy, defined, 238
- Inspiratory pressure, in mechanical ventilation, 432
- Inspiratory time, lengthening of, strategies for, 413-415
- Integrin(s), β_2 , in sepsis-induced lung injury, 221
- in lipopolysaccharide-induced sepsis syndrome, 190-191
- Intensive care, for HIV patients, 627-629
- Interbronchial aspiration, 597
- Intercellular adhesion molecule-1, in sepsis-induced lung injury, 221
- Interferon-gamma, in lipopolysaccharide-induced sepsis syndrome, 189-190
- Interleukin-1, in systemic inflammatory response syndrome, 155-156
- Interleukin-6, in systemic inflammatory response syndrome, 156

- Interleukin-1, as inflammatory mediator in sepsis, 204
 Interleukin-1 β , in lipopolysaccharide-induced sepsis syndrome, 187-188
 Interleukin-1 receptor antagonists, for sepsis, 312-313
 in lipopolysaccharide-induced sepsis syndrome, 188
 Interleukin-6, for sepsis, 313
 in lipopolysaccharide-induced sepsis syndrome, 188-189
 Interleukin-8, as inflammatory mediator in sepsis, 204
 for sepsis, 313
 in lipopolysaccharide-induced sepsis syndrome, 189
 Interleukin-10, as inflammatory mediator in sepsis, 204
 in lipopolysaccharide-induced sepsis syndrome, 189
 Intermittent mandatory ventilation (IMV), in weaning from mechanical ventilation, 482-483
 Intermittent positive-pressure ventilation (IPPV), for COPD patients with acute respiratory failure, 517-518
 Interstitial lung disease (ILD), AIDS-related, 634
 HIV infection in illicit drug users and, 801
 Intrapulmonary vascular dilatation, mechanism of, in hepatopulmonary syndrome, 37-38
 Intrinsic PEEP. *See Auto-positive end-expiratory pressure (PEEP).*
 Intubation, 355-378
 endotracheal, equipment for, 362-366
 ethical issues related to, 372-373
 for prolonged airway management, 370-371
 medicolegal issues related to, 372
 retrograde endotracheal, 358, 359
 tracheal, techniques of, 355-361. *See also Tracheal intubation, techniques of.*
 translaryngeal. *See Translaryngeal intubation.*
 Isoniazid, for tuberculosis in HIV-infected patients, 700
 Isoproterenol, for sepsis, 282-283
 Isosporiasis, prevalence, trends in, 623

 Jet ventilation, high-frequency, in newborns, 610-611

 Kaposi's sarcoma, 755-758
 described, 755-756
 diagnosis, 756-757
 epidemiology, 756
 HIV infection in illicit drug users and, 804
 in HIV-infected children, 792
 in HIV-infected patients, fiberoptic bronchoscopy for, 777-778
 new developments in, 657
 pathogenesis, 756
 prevalence, trends in, 623
 prognosis, 757
 pulmonary, 756
 radiography of, 756
 treatment, 757-758
 Ketoconazole, for ARDS, 227
 Kupffer cell uptake, determinants of, during MOFS, 84-86
 Kupffer cell-hepatocyte interactions, 90-91

 Laryngeal mask airway (LMA), for endotracheal intubation, 365
 Laryngoscope blades, for endotracheal intubation, 362, 363
 Larynx, injuries of, translaryngeal intubation and, 368-369

 Left ventricular failure, as cause of difficulty in weaning from mechanical ventilation, 481-482
 Left ventricular function, in sepsis, 238-240, 242-243
 Legionella sp., in HIV-1 infection, 715
 Leukotriene(s), in systemic inflammatory response syndrome, 157
 Leukotriene B₄, in lipopolysaccharide-induced sepsis syndrome, 190
 Leukencephalopathy, prevalence, trends in, 623
 Lipid(s), metabolism of, in sepsis, 253-254
 Lipid A, in sepsis, 176
 Lipopolysaccharide(s), and induction of pulmonary intravascular macrophages in liver cirrhosis, 145
 entry into circulation, in sepsis-induced lung injury, 218
 sepsis syndrome due to, 183-184
 Lipopolysaccharide-CD14 interaction, sepsis syndrome due to, 184
 Liquid lung ventilation, 419
 Liver, dysfunction of, pulmonary pathophysiology associated with, 67-82
 nitric oxide and, 341-342
 Liver cirrhosis, 49-66. *See also Cirrhosis, liver.*
 Liver disease, chronic, lung vasculature changes in, 1-15
 pulmonary hypertension in, 17-33
 shunts in, 1-8
 cytokine biology in, 89
 experimental, intravascular phagocytosis in, 141-145
 in hepatopulmonary syndrome, 39
 pulmonary function testing in, 78-79
 pulmonary hypertension in, 8-12
 pulmonary intravascular phagocytosis in, 137-150.
See also Pulmonary intravascular phagocytosis.
 Liver transplantation, early post-transplant considerations, 103-109
 for α_1 -antitrypsin deficiency, 73
 for hepatopulmonary syndrome, 115-123. *See also Hepatopulmonary syndrome, liver transplantation for.*
 for pulmonary hypertension in chronic liver disease, 27-29
 gas exchange effects on, 61-62
 hypoxemia and, 99-100
 infectious complications, 106-109
 intraoperative considerations, 102-103
 late post-transplant considerations, 109-110
 lung-liver disorders and, 101
 malignancy and, 102
 noninfectious complications, 103-106
 pleural effusions and, 101-102
 pretransplant considerations, 99-102
 pulmonary complications, 99-114
 pulmonary edema and, 100-101
 pulmonary function abnormalities and, 102
 pulmonary hypertension and, 101
 Liver-lung disorders, in liver transplant recipients, 101
 L-selectin, in sepsis-induced lung injury, 220
 Lung(s), adenovirus infection of, 750
 compliance of, during mechanical ventilation, measurement of, 462-464
 damage to, ventilator-induced, 556-560
 Epstein-Barr virus of, in HIV-infection, 749
 HIV in, immunologic-related, 633-645
 mechanics of, during mechanical ventilation, measurement of, 462-470
 neutrophilic alveolitis effects on, 640-641
 resistance of, during mechanical ventilation, measurement of, 464
 Lung abscess, in illicit drug users, 801
 Lung cancer, in HIV-infected patients, 759-760

- Lung injury, acute, current concepts of, 213-235
 sepsis-induced, molecular pathogenesis, 217-226
 Lung injury score, components and individual values of, 214
 "Lung protective" strategies, using conventional ventilator capabilities, 411-413
 Lung separation, anatomic reasons for, 596-597
 physiologic reasons for, 597-599
 techniques of, 591-596
 Lung transplantation, cystic fibrosis and, acute respiratory failure associated with, noninvasive ventilation for, 525
 for α_1 -antitrypsin deficiency, 72-73
 lung separation due to, 597-598
 Lymphocyte(s), in lungs of HIV-infected patients, 634-638
 T, cytotoxic, in HIV infection, 637
 HIV infection of, 641-642
 lung epithelial damage due to, 637-638
 Lymphocytic alveolitis, HIV-related, 765-766
 pathogenesis, 635-636
 Lymphocytic interstitial pneumonitis, HIV infection in illicit drug users and, 804
 in HIV infection, 763-766
 in HIV-infected children, 791-792
 Lymphoma, non-Hodgkin's, 758-759. See also *Non-Hodgkin's lymphoma*.
 prevalence, trends in, 623
 MAC disease, disseminated, 702-705
 clinical presentation, 703-704
 diagnosis, 704
 epidemiology, 702-705
 management, 704
 pathogenesis, 703
 prevention, 704-705
 Macrophage(s), alveolar, in lungs of HIV-infected patients, 638-641
 pulmonary intravascular, 125-135. See also *Pulmonary intravascular macrophages*.
 Macrophage alveolitis, AIDS-related, mechanisms in, 638
 Malignancy, HIV-related, pulmonary complications, 755-761
 in liver transplant recipients, 102
 Markers, defined, 199
 of sepsis, 199-212. See also *Sepsis, markers of*.
 antioxidants, 205
 complement, 203
 cytokines, 203-204
 endothelial cells, 207-209
 endotoxin, 201-203
 epithelial cells, 208-209
 functions of, 199-200
 inflammation mediators and modulators, 201-205
 inflammatory cell activation, 205-209
 interpretation of studies of, problems related to, 200
 monocytes, 206-207
 neutrophils, 205-206
 oxidants, 205
 phospholipids, 204-205
 Mask ventilation, clinical application of, for COPD patients with acute respiratory failure, 518-522
 for COPD patients with acute respiratory failure, 516-518
 Massive hemoptysis, 596
 Maximum inspiratory airway pressure, during mechanical ventilation, measurement of, 462
 Measles pneumonia, in HIV-infection, 749-750
 Mechanical ventilation, acute respiratory distress due to, 441-442
 adjuncts to, 491-511
 for carbon dioxide removal, 492-498
 for improving oxygenation, 498-506
 future trends in, 506
 airway pressure release ventilation, 416-417
 airway resistance during, measurement of, 464
 auto-PEEP in, measurement of, 464-465
 barotrauma during, 445
 complications of, 439-451
 acute respiratory distress, 441-442
 blood from endotracheal tube, 446-447
 during initiation of positive-pressure ventilation, 439-440
 hypotension, 440-441
 hypoxemia, 445-446
 repeated high-pressure alarm, 442-445
 ventilator-associated pneumonia, 447-450
 conventional approach to, 555-556
 dynamic hyperinflation in, 429-430
 enhancements in pressure-limited breath, 415-416
 flow delivery in, 431-432
 gas exchange during, 453-460
 goals of, 423
 high-frequency ventilation, 417-419
 high-pressure alarm due to, 442-445
 hypotension due to, 440-441
 in ARDS, 229
 modes of, 570-571
 in COPD, 577-590. See also *Chronic obstructive pulmonary disease (COPD)*, mechanical ventilation in.
 liquid lung ventilation, 419
 long inspiratory time strategies, 413-415
 lung mechanics during, measurement of, 462-470
 lung protective strategies using conventional ventilator capabilities, 411-413
 monitoring during, 453-473
 ABGs in, 453-454
 airway occlusion pressure, 460
 airway pressure profile, 465
 capnography, 457-460
 flow-volume curves, 465-466
 of breathing pattern, 460-462
 of maximal inspiratory airway pressure, 462
 of respiratory neuromuscular function, 460-462
 pressure-time product, 467-470
 pulse oximetry, 454-457
 work of breathing, 467
 new modes of, 411-421
 neonatal. See *Newborns, mechanical ventilation of*.
 noninvasive, 486
 of newborns, 603-613. See also *Newborns, mechanical ventilation of*.
 oxygenation during, 445
 patient agitation during, causes, 425
 patient-related factors in, 423-430
 respiratory center output, 423-426
 respiratory system mechanics, 426-430
 pneumothorax due to, 444
 posttrigger phase of, 430
 pressure-controlled, 400-403
 proportional-assist ventilation, 419
 trigger phase of, 430
 ventilator-related factors in, 430
 apparatus resistance, 432
 flow delivery, 431-432
 inspiratory pressure, 432
 tidal volume, 432

- ventilator triggering, 430-431
- volume-cycled, 395-400. *See also* *Volume-cycled ventilation*.
- weaning from, 475-489
 - computer-assisted, 486
 - conditions required for, 475-478
 - difficult-to-wean patients, 484-486
 - incidence, 484
 - management, 484-486
 - difficulty in, postextubation respiratory failure and, 533-535
 - extubation criteria in, 478
 - future developments in, 486
 - intermittent mandatory ventilation in, 482-483
 - methods of, 482-484
 - outcome of, predictive indexes of, 477
 - pressure-support ventilation in, 483
 - problems related to, 478-482
 - pulmonary gas exchange in, 476
 - respiratory system capacity in, 476-478
 - T-piece trials in, 482
- Mediastinal infections, in illicit drug users, 801
- Medicolegal issues, in intubation, 372
- Metabolic disorders, inherited, α_1 -antitrypsin deficiency, 151-152
 - hepatopulmonary syndrome, 152-155
- Metabolism, alterations in, sepsis-induced, altered calcium homeostasis in, 255-257
- Methylprednisolone, for sepsis, 180
- Microbe(s), nitric oxide and, 337-339
- Midazolam, for translaryngeal intubation, 366
- MIGET. *See* *Multiple inert gases elimination technique*.
- Minitracheostomy, 360, 362
- MOFS. *See* *Multiple organ failure syndrome*.
- Monocyte(s), in inflammatory cell activation in sepsis, 206-207
- Mucormycosis, 741
- Multiple inert gases elimination technique (MIGET), in liver cirrhosis, 51-55
- Multiple organ failure syndrome (MOFS), cardiopulmonary homeostasis during, gut-liver axis of, 84-86
 - sepsis-induced, hepatic production and export of inflammatory mediators in, 88-90
 - lung-liver interactions in, 83-98
 - described, 83
 - Q_L, 86-88
- Multiple-organ dysfunction syndrome (MODS), ARDS in, 216
 - defined, 175
 - described, 249
- Multi-system organ failure (MSOF), in sepsis, 272
- Muscular dysfunction, as cause of difficulty in weaning from mechanical ventilation, 480-481
- Mycobacteria genavense*, nontuberculous mycobacterial infection in HIV-infected patients due to, 701, 705
- Mycobacteria haemophilum*, nontuberculous mycobacterial infection in HIV-infected patients due to, 701, 706
- Mycobacteria kansasii*, nontuberculous mycobacterial infection in HIV-infected patients due to, 701, 705
- Mycobacteria xenopi*, nontuberculous mycobacterial infection in HIV-infected patients due to, 701, 706
- Mycobacterial diseases, in HIV-infected patients, 701
- nontuberculous, 702
- Mycobacteriosis, nontuberculous, prevalence, trends in, 623
- Mycobacterium avium* complex (MAC), new developments in, 656-657
- Mycobacterium avium*-intracellular infection, in HIV-infected children, 790
- Myocardial dysfunction, mechanism of, 243-245
- Myocardium, nitric oxide and, 341
- Naloxone, for sepsis, 299-300
- Narcotics, for translaryngeal intubation, 366
- Neonates. *See* *Newborns*.
- Neurologic disorders, as cause of difficulty in weaning from mechanical ventilation, 478
- Neuromuscular blockade, for translaryngeal intubation, 367
- Neutrophil(s), functions of, granulocyte colony-stimulating factor and, 322-323
 - in inflammatory cell activation in sepsis, 205-206
 - organ injury due to, 327-328
- Neutrophilic alveolitis, in HIV-infected patients, 640
- lung damage due to, 640-641
- Newborns, mechanical ventilation of, 603-613
 - carbon dioxide removal in, 608-609
 - conventional, application of, 607-609
 - high-frequency techniques, application of, 609-611
 - carbon dioxide removal during, 611
 - jet ventilation, 610-611
 - oscillation, 611
 - oxygenation during, 611
 - positive-pressure ventilation, 610
 - history of, 604-607
 - monitoring of, 609
 - oxygenation in, 608
 - ventilators in, 607
- Nitric oxide, and endothelial activation, 341
 - and gut, 342
 - and immunity, 342
 - and liver, 341-342
 - and microbes, 337-339
 - and myocardium, 341
 - described, 333
 - during inflammatory reaction, 336-337
 - during septic shock, 339-342
 - for improving oxygenation, in mechanical ventilation, 498-499
 - in ARDS, 568-570
 - in hepatopulmonary syndrome, 154-155
 - in lipopolysaccharide-induced sepsis syndrome, 190
 - in sepsis, 333-350
 - in vasoplegia, 340-341
 - inducible, 342-343
 - regulation of, 336
 - inhaled, for ARDS, 228
 - manipulation of, in sepsis, 343-345
 - physiologic targets of, 335-336
- Nitric oxide synthases, 334-335
- Nocardia* sp., in HIV-1 infection, 715
- Non-Hodgkin's lymphoma, described, 758
 - diagnosis, 759
 - epidemiology, 758
 - HIV infection in illicit drug users and, 804
 - in HIV-infected patients, 758-759
 - pathogenesis, 758-759
 - pathology of, 758-759
 - prognosis, 759
 - pulmonary involvement in, 759
 - treatment, 759
- Noninvasive ventilation, advantages of, 542-544
 - comfort of patient, 537
 - cost-effectiveness of, 545
 - disadvantages of, 544-545
 - education and implementation of, 545
 - in acute respiratory failure, 513-553

Noninvasive ventilation (*Continued*)

- in asthmatics, 522-524
 - in AIDS patients, 530-531
 - in ARDS, 528-529
 - in atelectasis, 532
 - in community-acquired pneumonia, 531-532
 - in COPD, 516-522
 - in cystic fibrosis, 525
 - in hypercapnic respiratory failure, 516
 - in hypoxemic respiratory failure, 525-526
 - in pediatric hypoxemic acute respiratory failure, 532-533
 - in postoperative respiratory failure, 529-530
 - in trauma patients, 530
 - interface in, 535-537
 - masks for, 536
 - mode of, 537
 - monitoring during, 541-542
 - patient selection for, 535
 - portable ventilators for, 540
 - predictors of success, 542
 - weaning from, 542
- Nonspecific interstitial pneumonitis, in HIV infection, 764-765
- NUCA 3001, for HIV infection, 651
- NUCA 3002, for HIV infection, 653
- NUCB 3002, for HIV infection, 653

- Octreotide, gas exchange effects on, 60
- Oscillation, high-frequency, in newborns, 611
- Oxidant(s), as inflammatory mediator in sepsis, 205
- Oxygen, utilization of, in sepsis, 250-251
- Oxygen consumption, during sepsis, 263-278
- management, 274-275
 - oxygen delivery and, relationship between, 263-271
- Oxygen delivery, during sepsis, 263-278
- management, 274-275
 - oxygen consumption and, relationship between, 263-271
- Oxygenation, during high-frequency ventilation in newborns, 611
- in mechanical ventilation, adjuncts for improving, 498-506
 - in neonatal mechanical ventilation, 608

- Paracentesis(es), large-volume, pulmonary function changes following, 77-78
- Paracoccidioidomycosis, 737-738
- clinical features, 738
 - diagnosis, 738
 - epidemiology, 738
 - microbiology of, 737-738
 - prevention, 738
 - treatment, 738
- Parasitic infections, in HIV-infection, 750-751
- Partial liquid ventilation, in ARDS, 567-568
- Patient-ventilator interactions, 423-438. *See also*
- Mechanical ventilation, patient-related factors in;*
 - Mechanical ventilation, ventilator-related factors in.*
- improvements in, strategies for, 432-435
- Pentamidine, for *Pneumocystis carinii* pneumonia, 681-684
- for sepsis, 179
- Pentoxifylline, for sepsis, 294
- Percutaneous dilatational tracheostomy, 359-360, 361
- Perflubron, for ARDS, 227-228

- Perfluorocarbon-associated gas exchange, for improving oxygenation, in mechanical ventilation, 502-504
- Permissive hypercapnia, in ARDS, 565
- Phagocytosis, pulmonary, intravascular, in humans, 146-147
- pulmonary intravascular. *See Pulmonary intravascular phagocytosis.*
- Phenylephrine, for sepsis, 282
- gas exchange effects on, 60
- Phospholipid(s), as inflammatory mediator in sepsis, 204-205
- Phycon Univent tube, for endotracheal intubation, 362, 363
- Piperacillin, for sepsis, 179
- Plasmapheresis, gas exchange effects on, 60
- Platelet-activating factor (PAF), in hepatopulmonary syndrome, 154
- in lipopolysaccharide-induced sepsis syndrome, 190
 - in systemic inflammatory response syndrome, 157
- Platelet-activating factor antagonists, for sepsis, 292-294
- Pleural disease, in pulmonary disease evaluation in HIV-infected patients, 778-780
- Pleural effusion(s), 76-77
- following liver transplantation, 104
 - in liver transplant recipients, 101-102
- Pleural infections, in illicit drug users, 801
- Pneumocystis carinii* pneumonia, 665-695
- acute respiratory failure in, prognostic markers of, 676-678
 - AIDS and, 621
 - biology of, 665-669
 - cell structure of, 666
 - chemoprophylaxis, 684-686
 - clinical manifestations, 669-680
 - clinical presentation, 670-672
 - disease severity, prognostic markers of, 676-678
 - epidemiology, 668-669
 - extrapulmonary infection in, 678-679
 - following liver transplantation, 108-109
 - historical perspective, 665
 - HIV-related deaths due to, 621
 - host pulmonary defense mechanisms in, 667-668
 - host-pathogen interactions in, 666-667
 - in HIV-infected children, 788-789
 - in HIV-infected patients, blood tests for, 772
 - sputum examination for, 773
 - in HIV-seropositive patients, incidence, 669-670
 - risk of, 670
 - intensive care of patients with, 627-628
 - life cycle of, 666
 - new developments in, 655-656
 - pathologic manifestations, 679-680
 - pulmonary function tests in, 672-673
 - pulmonary processes with, 680
 - radiographic manifestations, 673-676
 - taxonomy of, 665-666
 - treatment, 680-686
 - clindamycin-primaquine, 682-683
 - corticosteroids, 683-684
 - empiric versus diagnostic-directed, 680-681
 - TMP-SMZ, 681-684
 - trimethoprim-dapsone for, 683
 - trimetrexate, 683
- Pneumocystis*, prevalence, trends in, 623
- Pneumonia, atypical, in HIV infection, 751
- bacterial, following liver transplantation, 106-107
 - in HIV-type 1 infection, 713-723. *See also Human immunodeficiency virus (HIV) infection-type 1, bacterial pneumonia associated with.*
- prevalence, trends in, 623

- community-acquired, acute respiratory failure in, non-invasive ventilation for, 531-532
- fungal, following liver transplantation, 109
- in illicit drug users, 801
- measles, in HIV infection, 749-750
- nosocomial, in HIV-type 1 infection, 715-716
- Pneumocystis carinii*, 665-695. See also *Pneumocystis carinii* pneumonia.
- following liver transplantation, 108-109
- ventilator-associated, 447-450
- viral, in illicit drug users, 801
- Pneumonitis, CMV, in HIV infection, 746-748
- HSV, in HIV infection, 748-749
- lymphocytic interstitial, HIV infection in illicit drug users and, 804
- in HIV infection, 763-766
- in HIV-infected children, 791-792
- nonspecific interstitial, in HIV infection, 764-765
- VZV, in HIV infection, 749
- Pneumothorax, in ventilated patients, 444
- Portal hypertension, noncirrhotic, 76
- Positive end-expiratory pressure (PEEP), application of, determination of, 391-393
- external, in COPD, 580-581
- in ARDS, 560-561
- in ventilatory failure, 379
- Positive-pressure ventilation, high-frequency, in newborns, 610
- initiation of, problems during, 439-440
- noninvasive, clinical application of, 520-522
- Positive-pressure ventilatory support, lung-liver interactions during, 86-88
- Preload, defined, 238
- Pressure-controlled ventilation, 400-403
- auto-PEEP in, 401, 403
- clinical studies, 406-408
- indications, 408
- inspiratory resistance in, 401
- inspiratory time in, 401
- respiratory system compliance in, 401
- tidal volume determinants in, 401-403
- to volume-cycled ventilation, mode interconversion, 403-406
- versus volume-cycled ventilation, 395
- Pressure-limited breath, enhancements in, 415-416
- Pressure-support ventilation, in weaning from mechanical ventilation, 483
- Pressure-time product, during mechanical ventilation, measurement of, 467-470
- Pressure-volume curves, during mechanical ventilation, measurement of, 461-462
- Primary biliary cirrhosis (PBC), 74-75
- Prone positioning, for improving oxygenation, in mechanical ventilation, 504-506
- in ARDS, 566-567
- Propofol, for translaryngeal intubation, 366-367
- Proportional-assist ventilation, 419
- Prostacyclin, inhaled, in ARDS, 568-570
- Prostaglandin metabolites, in lipopolysaccharide-induced sepsis syndrome, 190
- Protein(s), metabolism of, in sepsis, 253
- Protein synthesis, hepatic acute-phase, inflammatory response modulation by, 91-93
- Proteinosis, pulmonary alveolar, 596-597
- P-selectin, in sepsis-induced lung injury, 220
- Pulmonary alveolar proteinosis, 596-597
- Pulmonary angiography, in hepatopulmonary syndrome, 42-44
- Pulmonary artery hypertension, 17
- Pulmonary calcifications, following liver transplantation, 105-106
- Pulmonary cells, pathogenesis, retroviral infection of, 641
- Pulmonary circulation, alterations in, cirrhosis-associated, pulmonary intravascular macrophages in, 144-145
- Pulmonary complications, in lungs of HIV-infected patients, 640-641
- Pulmonary edema, cardiogenic, acute respiratory distress in, noninvasive ventilation for, 526-528
- HIV infection in illicit drug users and, 802-803
- in liver transplant recipients, 100-101
- Pulmonary embolism, septic, in illicit drug users, 800-801
- Pulmonary function, abnormalities associated with, in liver transplant recipients, 102
- Pulmonary function tests, in liver disease, 78-79
- in *Pneumocystis carinii* pneumonia, 672-673
- in pulmonary disease evaluation in HIV-infected patients, 771
- Pulmonary gas exchange, in weaning from mechanical ventilation, 476
- Pulmonary hyperinflation, in COPD, 581-585
- Pulmonary hypertension, defined, 17
- histology, 18-19
- subclassification of lesions, 19
- history of, 17-18
- in chronic liver disease, 17-33
- causes, 20-21
- demographics, 19-20
- diagnosis, 22-24
- endothelial cell, 21-22
- features, 25
- liver transplantation for, 27-29
- natural history, 25-26
- pharmacotherapy, 24-25
- prognostic factors, 26-27
- survival following, 25
- in liver disease, 8-12
- in liver transplant recipients, 101
- incidence, 19-20
- pulmonary intravascular phagocytosis and, 147
- Pulmonary infections, in illicit drug users, 799-801
- Pulmonary intravascular macrophages, as source of inflammatory mediators, 131
- described, 125
- in acute lung injury, 125-135
- experimental approaches to, 131-133
- induction of, 132-133
- isolation for in vitro study, 131-132
- phagocytic function, 127
- role of, 128-131
- in cirrhosis-associated pulmonary circulatory alterations, 144-145
- in liver cirrhosis, induction of, mechanisms for, 145-146
- in pulmonary intravascular phagocytosis in chronic liver disease, 144
- in sheep, inactivation of depletion of, 133
- liver-lung interactions in species with, 130-131
- species distribution of, 128
- Pulmonary intravascular phagocytosis, and ARDS, 148-149
- clinical consequences, 147-149
- described, 137
- in humans, 146-147
- in liver disease, 137-150
- pulmonary intravascular macrophages in, 144
- Pulmonary lymphoid hyperplasia, in HIV-infected children, 791-792
- Pulmonary system, HIV infection effects on. See Human immunodeficiency virus (HIV) infection, pulmonary complications.

- Pulmonary vascular disease, HIV infection in illicit drug users and, 802
- Pulse oximetry, accuracy of, 454-455
clinical applications of, 456-457
in pulmonary disease evaluation in HIV-infected patients, 772
limitations of, 455-456
principles of, 454
- Q_L in sepsis-induced MOFS, 86-88
- Radiology, interventional, gas exchange effects on, 60-61
- Radionuclide scans, in pulmonary disease evaluation in HIV-infected patients, 769-771
- Respiration, in HIV infection, 625-626
- Respiratory distress, acute, mechanical ventilation and, 441-442
- Respiratory failure, hypoxemic, noninvasive ventilation for, 525-526
postoperative, noninvasive ventilation for, 529-530
- Respiratory neuromuscular function, measurement of, during mechanical ventilation, 460-462
- Respiratory pump failure, as cause of difficulty in weaning from mechanical ventilation, 480-481
- Respiratory syncytial virus (RSV) infection, in HIV infection, 749
- Respiratory system capacity, in weaning from mechanical ventilation, 476-478
- Respiratory tract, infections of, in HIV-type 1 infection, 720
- Respiratory workload, increase in, as cause of difficulty in weaning from mechanical ventilation, 478-480
- Rest, gas exchange at, 50-55
- Retrograde endotracheal intubation, 358, 359
- Rhinovirus infection, in HIV infection, 750
- Rhodococcus* sp., in HIV-type 1 infection, 715
- Rib cage-abdominal motion, during mechanical ventilation, measurement of, 461
- Rifampin, for tuberculosis in HIV-infected patients, 700
- Right ventricular function, in sepsis, 240-243
- Rubeola, in HIV infection, 749-750
- Sedative(s), for translaryngeal intubation, 366-367
- Selectin(s), counter-receptors for, in sepsis-induced lung injury, 220-221
in sepsis-induced lung injury, 219-220
- Sepsis. See also *Sepsis syndrome*.
N-acetylcysteine for, 297-299
anti-cytokines for, 310-313
anti-endotoxins for, 309-310
antioxidants for, 295-297
ARDS in, 213-235
frequency of, 215-216
treatment, 228
aspirin for, 290-291
blood cultures in, 177-178
bradykinin antagonists for, 200
by-products of, hepatic control of, 84-88
clinical studies of, problems related to, 200
colony-stimulating factors in, 320
current concepts of, 213-235
cyclooxygenase inhibitors for, 289-292
defined, 175
described, 213
diagnosis, 177-178
early detection of, 199-212
energy substrate utilization alterations in, 249-255
fluid management in, 279-281
fungal, hepatic cytokine production in, 89-90
glucose metabolism in, 251-253
granulocyte colony-stimulating factor and modulation of inflammatory cells in, 319-332
granulocyte colony-stimulating factors in, 320-322
hemodynamic support during, 279-287
human models of, 245-246
ibuprofen for, 291-292
immunotherapy for, 307-317
incidence, 176-177, 213
inflammatory cell activation in, markers of, 205-206
interleukin-1 receptor antagonists for, 312-313
interleukin-6 for, 313
interleukin-8 for, 313
left ventricular function in, 238-240, 242-243
lipid metabolism in, 253-254
lung injury due to, molecular pathogenesis, 217-226
markers of, 199-212. See also *Markers, of sepsis*.
defined, 199
functions of, 199-200
interpretation of studies of, problems related to, 200
metabolic alterations in, altered calcium homeostasis in, 255-257
metabolic consequences of, 249-261
future directions in, 257-258
MOFS due to, 83-98. See also *Multiple organ failure syndrome (MOFS), sepsis-induced*.
multi-system organ failure in, 272
naloxone for, 299-300
nitric oxide in, 333-350
oxygen consumption during, 263-278
oxygen delivery during, 263-278
oxygen utilization in, 250-251
pathogenesis, 183-197
pathophysiology, 176
pentoxifylline for, 294
platelet-activating factor antagonists for, 292-294
protein metabolism in, 253
right ventricular function in, 240-243
sputum culture in, 178
treatment, 178-180
pharmacologic, 289-305
tumor necrosis factor for, 311-312
urine specimen in, 178
vasopressors for, 282-286
- Sepsis syndrome. See also *Sepsis*.
defined, 183
initiators of, 183-184
lipopolysaccharide-induced, 183-184
adhesion molecules in, 190-191
arachidonic acid metabolites in, 190
complement in, 190
cytokine induction in, 185-190
Fcγ receptors in, 191
immunologic mediators of, 184-191
integrins in, 190-191
interferon-gamma in, 189-190
interleukin-1β in, 187-188
interleukin-1 receptor antagonist in, 188
interleukin-6 in, 188-189
interleukin-8 in, 189
interleukin-10 in, 189
leukotriene B₄ in, 190
nitric oxide in, 190

- platelet-activating factor in, 190
 prostaglandin metabolites in, 190
 tumor necrosis factor- α in, 185-186
 tissue hypoxia in, supernormal oxygen delivery and, 271-274
 treatment, antibiotics, 178-180
 general approach to, 175-181
 Septic shock, cardiac dysfunction during, 237-248
 prognosis, 243
 treatment, implications for, 246-247
 death due to, causes, 237
 defined, 175
 nitric oxide during, 339-342
 Septicemia, prevalence, trends in, 623
 Sheep, pulmonary intravascular macrophages in, inactivation of depletion of, 133
 Shock, classification of, 237, 238
 defined, 237
 septic. *See Septic shock.*
 Shunt(s), in chronic liver disease, 1-8
 pathways for, 1-8
 Shunting, arteriovenous, in liver cirrhosis, 50-51
 Sinusitis, translaryngeal intubation and, 368
 Sleep apnea, acute respiratory failure in, noninvasive ventilation for, 524-525
 Somatostatin analogue, gas exchange effects on, 60
 Sporotrichosis, 739
 Sputum culture, in sepsis, 178
Streptococcus pneumoniae, in HIV-type 1 infection, 713, 714-715
 Stress, hepatic oxidative nonbacteremic versus bacteremic, cytokine kinetics during, 90
 Strongyloidiasis, pulmonary, in HIV infection, 751
 Stylet(s), illuminating, for endotracheal intubation, 365, 366
 Substance P, in hepatopulmonary syndrome, 154
 Surfactant, in ARDS, 566
 Surfactant replacement, for ARDS, 227
 Surfactant replacement therapy, for improving oxygenation, in mechanical ventilation, 499-502
 Systemic inflammatory response (SIRS), defined, 175
 Systemic inflammatory response syndrome (SIRS), mediators in, 155-157

 T lymphocytes, cytotoxic, in HIV infection, 637
 HIV infection of, 641-642
 lung epithelial damage due to, 637-638
 Technetium-^{99m} macroaggregated albumin body scan, in hepatopulmonary syndrome, 41
 The germinal matrix, 603
 Thoracic wall abnormality, as cause of difficulty in weaning from mechanical ventilation, 480
 Thoracoscopy, in pulmonary disease evaluation in HIV-infected patients, 778
 Thoracotomy, in pulmonary disease evaluation in HIV-infected patients, 778
 Tidal compliance, in ARDS, 563
 Tidal recruitment, in ARDS, 563
 Tidal volume, in mechanical ventilation, 432
 minimization of, 413
 pressure limitation for, implications of, 563-564
 TMP-SMZ. *See Trimethoprim-sulfamethoxazole.*
 Tobramycin, for sepsis, 179
 Toxoplasmosis, prevalence, trends in, 623
 pulmonary, in HIV-infection, 750
 T-piece trials, in weaning from mechanical ventilation, 482
 Tracheal extubation, 369-370
 Tracheal gas insufflation, in ARDS, 568
 in mechanical ventilation, 496-498
 Tracheal intubation, techniques of, 355-361
 cricothyroidectomy, 360
 endotracheal tube exchange over a catheter, 359, 361
 minitracheostomy, 360, 362
 percutaneous dilatational tracheostomy, 359-360, 361
 preparation for, 355-357
 retrograde endotracheal intubation, 358, 359
 with flexible fiberoptic bronchoscope, 358
 with gum elastic bougie, 359, 360
 Tracheostomy, percutaneous dilatational, 359-360, 361
 Tracheotomy, for prolonged airway management, 371-372
 Transient hypoxemia, noninvasive ventilation and, 544-545
 Translaryngeal intubation, complications of, in critically ill patients, 367-369
 credentialing in, 373
 laryngeal injury due to, 368-369
 pharmacologic agents for, 366-367
 preparation for, 355-357
 sinusitis due to, 368
 training in, 373
 with flexible fiberoptic bronchoscope, 358
 Transplantation, liver. *See Liver transplantation.*
 lung, cystic fibrosis and, acute respiratory failure associated with, noninvasive ventilation for, 525
 for α_1 -antitrypsin deficiency, 72-73
 lung separation due to, 597-598
 Transthoracic needle aspiration (TTNA), in pulmonary disease evaluation in HIV-infected patients, 778
 Trauma, acute respiratory failure in, noninvasive ventilation for, 530
 Trimethoprim-dapsone, for *Pneumocystis carinii* pneumonia, 683
 Trimethoprim/sulfamethoxazole (TMP/SMZ), adverse reactions to, 681-682
 for *Pneumocystis carinii* pneumonia, 681-684
 for sepsis, 179
 Trimetrexate, for *Pneumocystis carinii* pneumonia, 683
 Tuberculin skin testing, in HIV-infected patients, 699
 Tuberculosis, in HIV-infected children, 789-790
 in HIV-infected patients, 697-702
 bacteriologic and histologic examinations in, 699-700
 blood tests for, 772
 causative agents, 700-702
 clinical features, 699
 fiberoptic bronchoscopy for, 776
 incidence, 697-698
 prevalence, 697-698
 prevention, 702
 radiographic features, 699
 sputum examination for, 773-775
 treatment, 700
 in illicit drug users, 800
 multidrug-resistant organisms and, 700-702
 pathogenesis, in HIV-infected patients, 698-699
 prevalence, trends in, 623
 Tumor necrosis factor- α , in lipopolysaccharide-induced sepsis syndrome, 185-190
 Tumor necrosis factor (TNF), as inflammatory mediator in sepsis, 203-204
 for sepsis, 311-312
 in systemic inflammatory response syndrome, 156-157

Unilateral lung disease, lung separation due to, 597
 Univent tube, in lung separation, 591-592
 Urine specimen, in sepsis, 178

Valacyclovir, for CMV, 660
 Vancomycin, for sepsis, 179
 Varicella zoster virus (VZV), following liver transplantation, 108
 Varizella zoster virus (VZV) pneumonitis, in HIV infection, 749
 Vasoactive intestinal peptide (VIP), in hepatopulmonary syndrome, 153
 Vasodilator(s), for ARDS, 227
 Vasoplegia, nitric oxide in, 340-341
 Vasopressor(s), for sepsis, 282-286
 Venovenous intravena caval oxygenator, in mechanical ventilation, 494-496
 Ventilation, airway pressure release (APRV), 416-417
 equipment for, 362-366
 high-frequency, 417-419
 in ARDS, 563-566
 independent lung, 591-601
 intermittent mandatory, in weaning from mechanical ventilation, 482-483
 liquid lung, 419
 mask. See *Mask ventilation*.
 mechanical. See *Mechanical ventilation*.
 in ARDS, 229
 noninvasive, in acute respiratory failure, 513-553. See also *Noninvasive ventilation, in acute respiratory failure*.
 partial liquid, in ARDS, 567-568
 positive-pressure, initiation of, problems during, 439-440
 preset pressure. See *Pressure-controlled ventilation*.
 pressure-controlled. See *Pressure-controlled ventilation*.
 pressure-support, in weaning from mechanical ventilation, 483
 prone position, in ARDS, 229-230
 proportional-assist, 419
 volume-cycled. See *Volume-cycled ventilation*.
 Ventilation-perfusion (VA/Q) mismatching, in liver cirrhosis, 51
 Ventilator(s), lung damage due to, 556-560
 neonatal versus adult, 607
 portable, for noninvasive ventilation, 540
 Ventilator triggering, 430-431
 Ventilatory support, for ARDS, 555-575. See also *Acute respiratory distress syndrome (ARDS), ventilatory management of*.

 weaning from, 475-489. See also *Mechanical ventilation, weaning from*.
 Ventricular compliance, defined, 238
 Viral infections, in HIV-infected children, 790-791
 pulmonary, in HIV infection, 745-754
 adenovirus infection, 750
 atypical pneumonia, 751
 Bordetella infections, 751
 herpesvirus infections, 746-749
 influenza, 749
 measles pneumonia, 749-750
 parasitic infections, 750-751
 primary infections, 745-746
 respiratory syncytial virus, 749
 rhinovirus infection, 750
 secondary infections, 746
 Viral pneumonia, in illicit drug users, 801
 Volume-cycled ventilation, 395-400
 auto-PEEP in, 396-398
 clinical studies, 406-408
 flow profile in, 399-400
 flow rate in, 398-399
 indications, 408
 inspiratory resistance in, 396
 mean airway pressure in, 398
 pressure determinants in, 396
 respiratory system compliance in, 396
 to pressure-controlled ventilation, mode interconversion, 403-406
 ventilator settings in, 398-399
 versus pressure-controlled ventilation, 395
 Volutrauma, 491
 versus barotrauma, in ARDS, 560
 VZV. See *Varizella zoster virus*.

 Weaning, from ventilatory support, 475-489. See also *Mechanical ventilation, weaning from*.
 Workload, respiratory, increase in, as cause of difficulty in weaning from mechanical ventilation, 478-480

 Zidovudine (AZT), described, 647
 for HIV infection, 647, 649-650
 Zygomycosis, 741

